Confirmatory study timing for cell and gene therapies gaining accelerated approval is not going to be mandated, new Office of Therapeutic Products Director Nicole Verdun said.
Verdun prefers that confirmatory trials be underway at the time of approval, but acknowledged there will be exceptions.